CYP1B1 enhances the resistance of epithelial ovarian cancer cells to paclitaxel in vivo and in vitro

Zhu,Zhuangyan; Mu,Yaqin; Qi,Caixia; Wang,Jian; Xi,Guoping; Guo,Juncheng; Mi,Ruoran; Zhao,Fuxi

doi:10.3892/ijmm.2014.2041

CYP1B1 enhances the resistance of epithelial ovarian cancer cells to paclitaxel in vivo and in vitro

Authors:
- Zhuangyan Zhu
- Yaqin Mu
- Caixia Qi
- Jian Wang
- Guoping Xi
- Juncheng Guo
- Ruoran Mi
- Fuxi Zhao
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Shanxi Datong University School of Medicine, Datong, Shanxi 037009, P.R. China , Institute of Immunology, Shanxi Datong University School of Medicine, Datong, Shanxi 037009, P.R. China, Department of Obstetrics and Gynecology, Tianjin Medical University General Hospital, Tianjin 300052, P.R. China
Published online on: December 16, 2014 https://doi.org/10.3892/ijmm.2014.2041
Pages: 340-348
Copyright: © Zhu et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ovarian cancer (OC) is the most frequent cause of mortality among gynecological malignancies, with a 5-year survival rate of approximately 30%. The standard regimen for OC therapy includes a platinum agent combined with a taxane, to which the patients frequently acquire resistance. Resistance arises from the oxidation of anticancer drugs by CYP1B1, a cytochrome P450 enzyme overexpressed in malignant OC. The aim of the present study was to determine the role of CYP1B1 expression in the drug resistance of OC to the taxane, paclitaxel (PTX). Immunohistochemical staining was used to assess CYP1B1 expression in a panel of ovarian samples (53 primary cancer samples, 14 samples of metastastic cancer, 30 benign tumor samples and 19 normal tissue samples). Semi-quantitative RT-PCR was also performed to determine CYP1B1 expression in several OC cell lines. Finally, we used proliferation and toxicity assays, as well as a mouse xenograft model using nude mice to determine whether α-naphthoflavone (ANF), a CYP1B1 specific inhibitor, reduces resistance to PTX. CYP1B1 was overexpressed in the samples from primary and metastatic loci of epithelial ovarian cancers. In some cell lines, PTX induced CYP1B1 expression, which resulted in drug resistance. Exposure to ANF reduced drug resistance and enhanced the sensitivity of OC cells to PTX in vitro and in vivo. The expression profile of CYP1B1 suggests that it has the potential to be a useful diagnostic marker and prognostic factor for malignant OC. The inhibition of CYP1B1 expression by specific agents may provide a novel therapeutic strategy for the treatment of patients resistant to PTX and may improve the prognosis of these patients.

View Figures

View References

1	American Cancer Society: Ovarian cancer. https://www.cancer.org/acs/groups/cid/documents/webcontent/003130-pdf.pdf. Accessed January 2, 2014.
2	Canevari S, Gariboldi M, Reid JF, Bongarzone I and Pierotti MA: Molecular predictors of response and outcome in ovarian cancer. J Gen Virol. 60:19–37. 2006.
3	Baldwin LA, Huang B, Miller RW, et al: Ten-year relative survival for epithelial ovarian cancer. Obstet Gynecol. 120:612–618. 2012. View Article : Google Scholar : PubMed/NCBI
4	Huang TC and Campbell TC: Comparison of weekly versus every 3 weeks paclitaxel in the treatment of advanced solid tumors: a meta-analysis. Cancer Treat Rev. 38:613–617. 2012. View Article : Google Scholar
5	Mouratidou D, Gennatas C, Michalaki V, et al: A phase III randomized study comparing paclitaxel and cisplatin versus cyclophosphamide and cisplatin in patients with advanced ovarian cancer. Anticancer Res. 27:681–685. 2007.PubMed/NCBI
6	Lewis DF: 57 varieties: the human cytochromes P450. Pharmacogenomics. 5:305–318. 2004. View Article : Google Scholar : PubMed/NCBI
7	Nebert DW, Wikvall K and Miller WL: Human cytochromes P450 in health and disease. Philos Trans R Soc Lond B Biol Sci. 368:201204312013. View Article : Google Scholar : PubMed/NCBI
8	Fujita K: Cytochrome P450 and anticancer drugs. Curr Drug Metab. 7:23–37. 2006. View Article : Google Scholar : PubMed/NCBI
9	Lynch T and Price A: The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician. 76:391–396. 2007.PubMed/NCBI
10	Androutsopoulos VP, Spyrou I, Ploumidis A, et al: Expression profile of CYP1A1 and CYP1B1 enzymes in colon and bladder tumors. PloS One. 8:e824872013. View Article : Google Scholar : PubMed/NCBI
11	Murray GI, Melvin WT, Greenlee WF and Burke MD: Regulation, function, and tissue-specific expression of cytochrome P450 CYP1B1. Annu Rev Pharmacol Toxicol. 41:297–316. 2001. View Article : Google Scholar : PubMed/NCBI
12	Murray GI, Patimalla S, Stewart KN, Miller ID and Heys SD: Profiling the expression of cytochrome P450 in breast cancer. Histopathology. 57:202–211. 2010. View Article : Google Scholar : PubMed/NCBI
13	Piotrowska H, Kucinska M and Murias M: Expression of CYP1A1, CYP1B1 and MnSOD in a panel of human cancer cell lines. Mol Cell Biochem. 383:95–102. 2013. View Article : Google Scholar : PubMed/NCBI
14	Shatalova EG, Klein-Szanto AJ, Devarajan K, Cukierman E and Clapper ML: Estrogen and cytochrome P450 1B1 contribute to both early- and late-stage head and neck carcinogenesis. Cancer Prev Res (Phila). 4:107–115. 2011. View Article : Google Scholar
15	Urbschat A, Paulus P, von Quernheim QF, et al: Vitamin D hydroxylases CYP2R1, CYP27B1 and CYP24A1 in renal cell carcinoma. Eur J Clin Invest. 43:1282–1290. 2013. View Article : Google Scholar : PubMed/NCBI
16	McFadyen MC, McLeod HL, Jackson FC, Melvin WT, Doehmer J and Murray GI: Cytochrome P450 CYP1B1 protein expression: a novel mechanism of anticancer drug resistance. Biochem Pharmacol. 62:207–212. 2001. View Article : Google Scholar : PubMed/NCBI
17	Downie D, McFadyen MC, Rooney PH, et al: Profiling cytochrome P450 expression in ovarian cancer: identification of prognostic markers. Clin Cancer Res. 11:7369–7375. 2005. View Article : Google Scholar : PubMed/NCBI
18	Rochat B, Morsman JM, Murray GI, Figg WD and McLeod HL: Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation? J Pharmacol Exp Ther. 296:537–541. 2001.PubMed/NCBI
19	McFadyen MC, Cruickshank ME, Miller ID, et al: Cytochrome P450 CYP1B1 over-expression in primary and metastatic ovarian cancer. Br J Cancer. 85:242–246. 2001. View Article : Google Scholar : PubMed/NCBI
20	Gibson P, Gill JH, Khan PA, et al: Cytochrome P450 1B1 (CYP1B1) is overexpressed in human colon adenocarcinomas relative to normal colon: implications for drug development. Mol Cancer Ther. 2:527–534. 2003.PubMed/NCBI
21	McFadyen MC, Melvin WT and Murray GI: Cytochrome P450 enzymes: novel options for cancer therapeutics. Mol Cancer Ther. 3:363–371. 2004.PubMed/NCBI
22	Scripture CD, Sparreboom A and Figg WD: Modulation of cytochrome P450 activity: implications for cancer therapy. Lancet Oncol. 6:780–789. 2005. View Article : Google Scholar : PubMed/NCBI
23	Vaclavikova R, Soucek P, Svobodova L, et al: Different in vitro metabolism of paclitaxel and docetaxel in humans, rats, pigs, and minipigs. Drug Metab Dispos. 32:666–674. 2004. View Article : Google Scholar : PubMed/NCBI
24	Rochat B: Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism. Clin Pharmacokinet. 44:349–366. 2005. View Article : Google Scholar : PubMed/NCBI
25	Foland TB, Dentler WL, Suprenant KA, Gupta ML Jr and Himes RH: Paclitaxel-induced microtubule stabilization causes mitotic block and apoptotic-like cell death in a paclitaxel-sensitive strain of Saccharomyces cerevisiae. Yeast. 22:971–978. 2005. View Article : Google Scholar : PubMed/NCBI
26	Sun X, Li D, Yang Y, et al: Microtubule-binding protein CLIP-170 is a mediator of paclitaxel sensitivity. J Pathol. 226:666–673. 2012. View Article : Google Scholar
27	Marsh S, Somlo G, Li X, et al: Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer. Pharmacogenomics J. 7:362–365. 2007. View Article : Google Scholar : PubMed/NCBI
28	Bournique B and Lemarie A: Docetaxel (Taxotere) is not metabolized by recombinant human CYP1B1 in vitro, but acts as an effector of this isozyme. Drug Metab Dispos. 30:1149–1152. 2002. View Article : Google Scholar : PubMed/NCBI
29	Singh PB, Ragavan N, Ashton KM, Basu P, Nadeem SM and Nicholson CM: Quantified gene expression levels for phase I/II metabolizing enzyme and estrogen receptor levels in benign prostate from cohorts designated as high-risk (UK) versus low-risk (India) for adenocarcinoma at this organ site: a preliminary study. Asian J Androl. 12:203–214. 2010. View Article : Google Scholar
30	Zahid M, Beseler CL, Hall JB, Levan T, Cavalieri EL and Rogan EG: Unbalanced estrogen metabolism in ovarian cancer. Int J Cancer. 134:2414–2423. 2013. View Article : Google Scholar : PubMed/NCBI
31	Piotrowska H, Myszkowski K, Ziolkowska A, et al: Resveratrol analogue 3,4,4′,5-tetramethoxystilbene inhibits growth, arrests cell cycle and induces apoptosis in ovarian SKOV-3 and A-2780 cancer cells. Toxicol Appl Pharmacol. 263:53–60. 2012. View Article : Google Scholar : PubMed/NCBI
32	Saini S, Hirata H, Majid S and Dahiya R: Functional significance of cytochrome P450 1B1 in endometrial carcinogenesis. Cancer Res. 69:7038–7045. 2009. View Article : Google Scholar : PubMed/NCBI
33	Huang Y and Fan W: IkappaB kinase activation is involved in regulation of paclitaxel-induced apoptosis in human tumor cell lines. Mol Pharmacol. 61:105–113. 2002. View Article : Google Scholar
34	Qiu B, Sun X, Zhang D, Wang Y, Tao J and Ou S: TRAIL and paclitaxel synergize to kill U87 cells and U87-derived stem-like cells in vitro. Int J Mol Sci. 13:9142–9156. 2012. View Article : Google Scholar : PubMed/NCBI